21 January 2026 - IntraBio today announced that the European Commission granted marketing authorisation to Aqneursa (levacetylleucine) for the treatment of neurological manifestations of Niemann-Pick type C disease, following a positive opinion from the CHMP of the EMA.

Aqneursa is approved in the European Union for use in adults and children aged 6 years and older weighing at least 20 kg. The approved indication includes use in combination with miglustat, or as monotherapy in patients where miglustat is not tolerated.

Read IntraBio press release